Authors
Ana Lucía Gómez Gila, Fernando Gómez-Peralta, Susana Pica Montesinos, Virginia Bellido, Roque Cardona-Hernandez, María Asunción Martínez-Brocca
Published in
Anales de pediatria. Pages 504341. Sep 18, 2026. Epub Sep 18, 2026.
Abstract
Type 1 diabetes (T1D) can be identified in preclinical stages through the detection of islet autoantibodies and staged before clinical onset. This evolving paradigm highlights the need for structured care models allowing coordinated identification, staging, and follow-up of individuals with positive islet autoimmunity. This document describes an Integrated Care Pathway (ICP) developed from the available scientific evidence and the national SED-SEEN-SEEP consensus on screening and monitoring of preclinical T1D. The model is organised into three core sub-processes (target population identification, autoantibody detection and confirmation, and clinical follow-up with staging) and one transversal support sub-process based on information systems and performance indicators. This ICP provides a structured, evaluable, and scalable framework for the homogeneous implementation of screening and follow-up of preclinical T1D.
PMID:
42760247
Bibliographic data and abstract were imported from PubMed on 19 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0